EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Exposure‐Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM

Andreas Lindauer, Eric Snoeck, Christian Laveille, Ignacio Ayani, Lourdes Ochoa Díaz de Monasterioguren, Marcos Almendros, Javier Martínez-González iD, Lourdes Anta iD, Ibón Gutierro

The Journal of Clinical Pharmacology · 2025-03 · 65 (3) · 350-360

DOI: 10.1002/jcph.6152 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 17.10.2024. Verfasst von Andreas Lindauer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Calvagone SAS, Chazay d'Azergues, France. Hauptthemen laut MEDLINE: Schizophrenia, Risperidone, Receptors, Dopamine D2, Antipsychotic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Laboratorios Farmacéuticos Rovi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dopamine D2 receptor occupancy (D2RO) significantly influences the clinical effectiveness and safety of many antipsychotic drugs. Maintaining a D2RO range of 65%‐80% provides the best antipsychotic effects while minimizing adverse reactions. Data from a Phase III trial were used to establish an exposure–response relationship for monthly intramuscular Risperidone ISM (75 and 100 mg) or placebo administered to adults with schizophrenia. Pharmacodynamic analysis was based on an E max model for Positive and Negative Syndrome Scale (PANSS) developed in NONMEM. Plasma concentrations of the active moiety were derived using a previously developed population pharmacokinetic model, which was used for D2RO simulations in conjunction with a published E max model. The optimal D2RO range (65%‐80%) was reached for the median within hours following the first injection of both Risperidone ISM doses. At steady state, median D2RO for both doses remained above 65% throughout the 28‐day dosing period and demonstrated lower variability than oral risperidone. PANSS response did not differ significantly between dose groups, most likely because active moiety concentrations had already reached the plateau of the concentration–response relationship. The pharmacokinetic/pharmacodynamic analysis showed a profound placebo effect (−11.7%), and an additional maximal drug effect (−6.6%) resulting in a total PANSS improvement over time of −18.3%. Pharmacokinetic/pharmacodynamic modeling quantified a PANSS improvement over time after Risperidone ISM administration. The response was not significantly different in either dose group, likely because D2RO was already above the proposed efficacy threshold (65%) within 1 h after the first Risperidone ISM injection and remained above this level following repeated administrations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaRisperidoneReceptors, Dopamine D2Antipsychotic AgentsHumansAdultInjections, IntramuscularMaleFemaleMiddle AgedDose-Response Relationship, DrugModels, BiologicalYoung AdultDouble-Blind Method

Stichwörter der Autor:innen

PANSSRisperidone ISMdopamine D2 receptor occupancymodeling and simulationpopulation PK/PDschizophrenia

Substanzen

RisperidoneReceptors, Dopamine D2Antipsychotic Agents

Autor:innen und Institutionen

  • Calvagone SAS, Chazay d'Azergues, France.
  • Luccio bv, Rozenlaan 26, Retie, 2470, Belgium.
  • Laboratorios Farmaceuticos ROVI, S.A., Alfonso Gómez, Madrid, Spain.

ORCID-Profile: Javier Martínez-González, Lourdes Anta

Förderung

  • Laboratorios Farmacéuticos Rovi

Zitieren

APA

Lindauer, A., Snoeck, E., Laveille, C., Ayani, I., de Monasterioguren, L. O. D., Almendros, M., Martínez-González, J., Anta, L., & Gutierro, I. (2025). Exposure‐Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM. The Journal of Clinical Pharmacology, 65(3), 350-360. https://doi.org/10.1002/jcph.6152

Vancouver

Lindauer A, Snoeck E, Laveille C, Ayani I, de Monasterioguren LOD, Almendros M, et al. Exposure‐Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM. The Journal of Clinical Pharmacology. 2025;65(3):350-360. doi:10.1002/jcph.6152

BibTeX
@article{Lindauer2025,
  author = {Lindauer, Andreas and Snoeck, Eric and Laveille, Christian and Ayani, Ignacio and de Monasterioguren, Lourdes Ochoa Díaz and Almendros, Marcos and Martínez-González, Javier and Anta, Lourdes and Gutierro, Ibón},
  title = {Exposure‐Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM},
  journal = {The Journal of Clinical Pharmacology},
  year = {2025},
  volume = {65},
  number = {3},
  pages = {350--360},
  doi = {10.1002/jcph.6152}
}
Kostenlos starten →